Danaher (DHR) TD Cowen 46th Annual Health Care Conference summary

Business performance and outlook

• Guidance for 2026 set at 3%-6% growth, led by high single-digit growth in bioprocessing and stabilization in life sciences and diagnostics end markets.

• Q1 is seen as the low point, with expected improvement throughout the year, especially in life sciences and biotech as funding flows recover.

• Even at 3% growth, high single-digit EPS growth and 100 basis points of operating margin expansion are expected, with further upside if growth exceeds the low end.

• Bioprocessing consumables remain strong, with equipment showing sequential order and sales growth, and reshoring expected to drive a years-long CapEx cycle.

• China bioprocessing is rebounding, driven by increased biotech activity and local manufacturing, with the company maintaining a leading position.

Strategic initiatives and acquisitions

• The Masimo acquisition is viewed as a specialty diagnostics play, leveraging a gold-standard pulse oximetry platform with strong IP and clinical data.

• Expected $50 million in revenue synergies and $125 million in cost synergies over five years, with high single-digit ROIC by year 5.

• The acquisition fits the company’s traditional model, with opportunities to enhance value through operational improvements and integration.

• The balance sheet remains strong, allowing for additional acquisitions even after Masimo, with a disciplined approach to strategic fit.

Market trends and segment insights

• Life sciences end markets are modestly improving, with pharma investment confidence returning and biotech funding flows increasing in the US and China.

• Research funding has stabilized, with NIH and university funding showing improvement.

• AI is seen as a long-term accelerator for pharma development, increasing drug pipeline yield and benefiting bioprocessing demand.

• Diagnostics outside China have shown consistent mid-single-digit growth, with China headwinds expected to abate by year-end.

• Cepheid’s syndromic panels are expanding the addressable market, with non-respiratory portfolio growing at double digits.